3
|
Cirillo M, Attanasio M, Paniccia R, Rizzello F, Coccia ME, Fatini C. Impact of cardiovascular burden on coagulation pathway in apparently healthy women planning oocyte donation. Clin Hemorheol Microcirc 2021; 79:531-539. [PMID: 34420940 DOI: 10.3233/ch-211108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Hormonal fertility treatments are associated with increased coagulation factors inducing procoagulant milieu and possibly thrombotic risk. OBJECTIVE To assess coagulation by ROTEM and coagulation tests in apparently healthy infertile women before oocyte donation procedure. METHODS We enrolled 51 women (Assisted Reproductive Technology Centre, Florence). ROTEM and coagulation parameters were assessed before the start of infertility treatment. RESULTS We divided women in 3 groups according to the number of cardiovascular risk factors: Group A (n = 10), Group B (n = 16), and Group C (n = 25). By considering ROTEM Extem test, a significantly increased of MCF, TPI, and G were observed in groups B (p = 0.005, p = 0.03, and p = 0.007) and C (p = 0.01, p = 0.05, and p = 0.005) in comparison to group A. As regards ROTEM Intem test, the TPI and G values were significantly higher in groups B and C in comparison to group A (p < 0.01). MCF by Fibtem test significantly increased in groups B and C than in group A (p = 0.004 and p = 0.002, respectively). FVIII, vWF:Ag and D-dimer values significantly increase according to the presence of≥2 risk factors. CONCLUSIONS Data from coagulative assessment permit to sensitively identify women with potentially procoagulable state, which represents a risk factor of thromboembolic event during hormone treatment.
Collapse
Affiliation(s)
- Michela Cirillo
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.,Centre for Assisted Reproductive Technology, Division of Obstetrics and Gynaecology, Careggi University Hospital, Florence, Italy
| | - Monica Attanasio
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.,Centre for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy
| | - Rita Paniccia
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.,Centre for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy
| | - Francesca Rizzello
- Centre for Assisted Reproductive Technology, Division of Obstetrics and Gynaecology, Careggi University Hospital, Florence, Italy
| | - Maria Elisabetta Coccia
- Centre for Assisted Reproductive Technology, Division of Obstetrics and Gynaecology, Careggi University Hospital, Florence, Italy.,Department of Clinical and Experimental Biomedical Sciences, University of Florence, Florence, Italy
| | - Cinzia Fatini
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.,Centre for Assisted Reproductive Technology, Division of Obstetrics and Gynaecology, Careggi University Hospital, Florence, Italy
| |
Collapse
|
6
|
Ghaderian SMH, Akbarzadeh R, Mohajerani F, Khodaii Z, Salehpour S. The implication of single-nucleotide polymorphisms in ovarian hyperstimulation syndrome. Mol Reprod Dev 2019; 86:964-971. [PMID: 31115963 DOI: 10.1002/mrd.23171] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Revised: 04/23/2019] [Accepted: 04/29/2019] [Indexed: 01/05/2023]
Abstract
Ovarian hyperstimulation syndrome (OHSS) is an undesirable complication in the course of ovarian stimulation. This kind of stimulation is aimed at acquiring a sufficient number of high-quality oocytes in in vitro fertilization (IVF). Whereas the predisposition to OHSS could be impacted by genetic polymorphisms in susceptible genes, the present study has been jointly conducted with an Iranian cohort to scrutinize its relevant implication. Genomic DNA was extracted from blood samples of patients with a normal ovarian response (NOR) or with OHSS. Samples were analyzed to detect polymorphisms MTHFR rs1801131, MTHFR rs1801133, AMHR2 rs2002555, LHCGR rs2293275, PGR rs10895068, and SERPINE1 rs1799889. Variations of MTHFR, AMHR2, LHCGR, and PGR genes were significantly associated with the developing OHSS. After correction for multiple analysis, this difference was not evident for PGR genotypes. The polymorphic alleles of MTHFR (rs1801131 C-allele and rs1801133 T-allele), AMHR2 (rs2002555 G-allele), and LHCGR (rs2293275 G-allele) were significantly more prevalent among patients with OHSS compared to those in the NOR group. In contrast, the minor allele of PGR single-nucleotide polymorphism (SNP) (rs10895068, A-allele) was more prominent among patients with a NOR than those with OHSS. No significant difference was observed in genotypes or alleles of SERPINE1 rs1799889. The observations indicated that the minor alleles of MTHFR, AMHR2, and LHCGR genes could be considered an independent risk factor in susceptibility to OHSS. Nevertheless, polymorphic allele in the PGR rs10895068 SNP contributes to preventing OHSS occurrence. Therefore, it can be argued that these genes have a significant impact on OHSS.
Collapse
Affiliation(s)
| | - Reza Akbarzadeh
- Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.,Institute of Anatomy, University of Lübeck, Lübeck, Germany
| | - Fatemeh Mohajerani
- Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
| | - Zohreh Khodaii
- Dietary Supplements and Probiotics Research Center, Alborz University of Medical Sciences, Karaj, Iran
| | - Saghar Salehpour
- Preventative Gynecology Research Center (PGRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
9
|
Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Miyata S, Kawamura T, Horiuchi H, Fukumoto Y, Shimokawa H. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension. Arterioscler Thromb Vasc Biol 2016; 36:1293-301. [DOI: 10.1161/atvbaha.115.306845] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 04/08/2016] [Indexed: 11/16/2022]
Affiliation(s)
- Nobuhiro Yaoita
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Kimio Satoh
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Taijyu Satoh
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Koichiro Sugimura
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Shunsuke Tatebe
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Saori Yamamoto
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Tatsuo Aoki
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Masanobu Miura
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Satoshi Miyata
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Takeshi Kawamura
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Hisanori Horiuchi
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Yoshihiro Fukumoto
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| | - Hiroaki Shimokawa
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., K. Satoh, T.S., K. Sugimura, S.T., S.Y., T.A., M.M., S.M., Y.F., H.S.), Clinical Pharmaceutics educational Center, Nihon Pharmaceutical University, Saitama, Japan (T.K.); and Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (H.H.)
| |
Collapse
|